Toward Spectacle-Free Cataract Surgery

18 Dec 2013

After a lull, or at least a single-minded focus on femtosecond lasers for a time, refractive surgery has gotten exciting again: the drive to spectacle-free outcomes for cataract patients (who have aged-out of their eligibility for other refractive procedures) is calling for solutions that offer precision and accuracy at every stage of treatment. Start-ups coming up with the solutions will be serving some gigantic markets.

The vibrant community of start-ups, venture capitalists, and physicians at the Ophthalmology Innovation Summit (OIS) that preceded the 2013 American Academy of Ophthalmology Annual Meeting in New Orleans in November presented a welcome contrast to the all too typical dreary tales coming from medtech start-ups seeking capital. According to data from Elsevier’s Strategic Transactions, which was presented by the meeting’s co-founder, ophthalmologist and venture capitalist Emmett Cunningham, MD, PhD (of Clarus Ventures), VCs still see great potential in ophthalmic companies, particularly those with medical devices, where $200 million had been invested in 2013 as of October, twice the amount that had been invested for all of the previous year. (See Exhibit 1.)

For the past several years, the most recent innovation in ophthalmic surgery – the femtosecond laser – has dominated ophthalmology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Final Chance To Have Your Say: Take Our Reader Survey This Week

17 Sep 2024

• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

22 Aug 2024

• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

09 Jul 2024

• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

06 Jun 2025

• By Elizabeth Orr

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.